Drug Trial Radar · NCT07594652
Medication Treatment of ADHD in Pediatric Epilepsy
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.
Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)Drug
all participants will receive active treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Global Impression-ImprovementTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kennedy Krieger Institute
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.